Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 12/20 | 0.60 |
| ▸ | DRD2 | P14416 | 11/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.60 |
| ▸ | HTR2A | P28223 | 10/20 | 0.60 |
| ▸ | HTR7 | P34969 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6795599 | 0.95 | HTR1A (0.54) | HTR1ADRD2KCNH2HTR2AHTR7 | |
| SCHEMBL5767939 | 0.91 | HTR1A (0.62) | HTR1ADRD2KCNH2HTR2AHTR7 | |
| Hydrochloric Acid SCHEMBL4881899 | 0.89 | HTR1A (0.60) | HTR1ADRD2KCNH2HTR2AHTR7 | |
| SCHEMBL5678980 | 0.86 | HTR1A (0.61) | HTR1ADRD2KCNH2HTR2AHTR7 | |
| SCHEMBL6204580 | 0.86 | HTR2A (0.68) | HTR1ADRD2KCNH2HTR2AHTR7 | |
| SCHEMBL9367637 | 0.85 | HTR1A (0.60) | HTR1ADRD2KCNH2HTR2AHTR7 | |
| Hydrochloric Acid SCHEMBL4891136 | 0.85 | HTR1A (0.59) | HTR1ADRD2KCNH2HTR2AHTR7 | |
| SCHEMBL6795579 | 0.85 | HTR1A (0.59) | HTR1ADRD2KCNH2HTR2AHTR7 | |
| SCHEMBL9367264 | 0.84 | HTR1A (0.58) | HTR1ADRD2KCNH2HTR2AHTR7 | |
| SCHEMBL6224447 | 0.84 | HTR2A (0.60) | HTR1ADRD2KCNH2HTR2AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142933-A1 | Oxindole substituted piperazine derivatives | FORREST GEORGE WILLIAM (CA) | 2004-07-22 | — | — | US | claimed |
| US-20040142933-A1 | Oxindole substituted piperazine derivatives | FORREST GEORGE WILLIAM (CA) | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142933-A1 | Oxindole substituted piperazine derivatives | OPRK1, OPRD1, CNR1 | HTR1A 13/4885DRD2 21/4885KCNH2 1205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.